No abstract

Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab Dear Editor, During the COVID-19 pandemic, physicians may not feel comfortable managing dermatological conditions with biological agents. No literature describing behavior of pre-existing chronic spontaneous urticaria (CSU) in COVID-19 patients has been reported up to June 20, 2020, in PubMed. We present a 54-year-old female with CSU and angioedema since September 2019. Her medical history was negative for use of nonsteroidal anti-inflammatory drugs or analgesics, and atopic diathesis (asthma, rhinitis, or dermatitis). Full urticaria work-up including C-reactive protein, serum IgE, complete blood count, D-dimer, thyroid, renal, and hepatic profile were within normal limits. At initial visit, uriticaria activity score (UAS) = 6 and urticaria control test (UCT) = 0, demonstrating severe CSU. She had previously failed levocetirizine 15 mg daily. After starting bilastine 80 mg daily, CSU activity decreased to UAS7 (UAS 7 days score = 06 and UCT = 12). In

This study presents a single center experience with livedoid vasculopathy (LV). A rare disease that can lead to severe quality of life impairment. Characterize clinical data of LV patients at the Dermatology Division at the University of São Paulo. A retrospective and transversal study was conducted, from 1 January 2005 to 31 December 2019. About 75 patients diagnosed as LV and confirmed by skin biopsy were included. Epidemiology, clinical appearance, histopathology data, and treatment history were observed. There were 78.66% Caucasian women, with a mean age of 39.9 years. Frequent cutaneous manifestations were ulcers, atrophic blanche-like scars, hyperpigmentation, purpuras, telangiectasias, and livedo racemosa. Pain, pruritus, and hypoesthesia were the main symptoms. After treatment, almost 40% of